RxDoctor Payments Data

James Dorado, MD

Internal Medicine · Westerville, OHNPI 1033194949

Payments from drug & device makers

$15,161in general payments, 2019–2025

Across 970 payments — averaging $15.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novo Nordisk$2K
  • AstraZeneca$1K
  • GSK$1K
  • Lilly USA, LLC$974
  • Johnson & Johnson$718
  • plus $7K from 49 others

What the payments were for

  • Food & beverage$15,116100%
  • Education$460%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)210$2,586
Novo Nordisk126$1,713
AstraZeneca(2 entities)74$1,444
GSK84$1,085
Lilly USA, LLC61$974
Johnson & Johnson47$718
Boehringer Ingelheim49$687
Pfizer30$510
Bayer19$385
Amgen26$384
Merck31$384
Ardelyx, Inc.5$318
Abbott17$287
Takeda Pharmaceuticals U.S.A., Inc.17$278
Endologix LLC2$253
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC13$253
Amarin Pharma, Inc.15$235
Novartis12$230
Xeris Pharmaceuticals, Inc.11$222
Exact Sciences8$195
Sanofi-aventis U.S. LLC11$170
Biohaven Pharmaceuticals, Inc.9$154
Jazz Pharmaceuticals Inc.2$139
Kowa Pharmaceuticals America, Inc.10$124
Currax Pharmaceuticals LLC9$122
Teva Pharmaceuticals USA, Inc.7$122
Astellas Pharma US Inc6$111
Medtronic5$107
Biohaven Pharmaceutical Holding Company Ltd.5$81
Nestle Healthcare Nutrition Inc.4$70
Endo Pharmaceuticals Inc.4$69
Phathom Pharmaceuticals, Inc.3$59
Axsome Therapeutics, Inc.3$54
Idorsia Pharmaceuticals US Inc3$51
Neos Therapeutics, LP3$50
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$50
Corcept Therapeutics2$44
Collegium Pharmaceutical, Inc.2$43
Actelion Pharmaceuticals US, Inc.2$41
Vivus LLC2$39
Seqirus USA Inc2$38
Aimmune Therapeutics, Inc.2$34
Lucid Diagnostics Inc.2$29
Otsuka America Pharmaceutical, Inc.1$28
Melinta Therapeutics, LLC1$25
Corium, LLC2$19
Shield Therapeutics Inc1$19
Shire North American Group Inc1$19
Genentech USA, Inc.1$18
Tris Pharma Inc1$18
Sanofi Pasteur Inc.1$16
Regeneron Healthcare Solutions, Inc.1$15
E.r. Squibb & Sons, L.L.C.1$15
Intra-sana Laboratories1$14
Romark Laboratories, LC1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,161 in reported general payments places this provider in the 95th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$93,841
Medicare patients
155
Services billed
3,207

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban47$55,740
JardianceEmpagliflozin50$55,088
OzempicSemaglutide49$53,230
TrulicityDulaglutide37$52,911
JanuviaSitagliptin Phosphate42$50,533
XareltoRivaroxaban23$32,468
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$22,699
FarxigaDapagliflozin Propanediol20$21,221
LinzessLinaclotide22$19,177
Tresiba Flextouch U-200Insulin Degludec20$12,496
Tresiba Flextouch U-100Insulin Degludec20$7,527
ShingrixVaricella-Zoster Ge/As01b/Pf14$3,343
Tizanidine Hcl29$2,635
Atorvastatin Calcium301$2,248
Naproxen14$2,238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$510$55,74047 claims
Boehringer IngelheimJardiance$687$55,08850 claims
Novo NordiskOzempic$1,713$53,23049 claims
Lilly USA, LLCTrulicity$974$52,91137 claims
MerckJanuvia$384$50,53342 claims
Johnson & JohnsonXarelto$718$32,46823 claims
GSKTrelegy Ellipta, Shingrix$1,085$26,04136 claims
AstraZenecaFarxiga$1,444$21,22120 claims
AbbVieLinzess$2,586$19,17722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Westerville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →